LITFULO

Growth

ritlecitinib

NDAORALCAPSULE
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

inhibitor. Ritlecitinib irreversibly inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib inhibits cytokine induced STAT phosphorylation mediated…

Clinical Trials (5)

NCT07226531N/ANot Yet Recruiting

Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

Started Feb 2026
300 enrolled
Alopecia Areata
NCT07228390Phase 2Recruiting

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

Started Nov 2025
240 enrolled
Hidradenitis Suppurativa
NCT07219615Phase 2Recruiting

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

Started Oct 2025
200 enrolled
Chronic Spontaneous Urticaria
NCT07029828Phase 3Recruiting

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

Started Sep 2025
140 enrolled
Severe Alopecia Areata
NCT07152119N/ARecruiting

A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.

Started Aug 2025
3,000 enrolled
Severe Alopecia Areata

Loss of Exclusivity

LOE Date
Oct 17, 2041
190 months away
Patent Expiry
Oct 17, 2041
Exclusivity Expiry
Jun 23, 2028

Patent Records (3)

Patent #ExpiryTypeUse Code
12077533
Dec 3, 2034
U-3994
9617258
Dec 3, 2034
SubstanceProduct
12116368
Oct 17, 2041
Substance